ProfoundBio Announces First Patient Dosed in Phase 1/2 Clinical Trial of PRO1107 ... - PR Newswire

Retrieved on: 2024-02-05 21:00:45

Tags for this article:

Biotechnology

Antibody-drug conjugates

Antibody-drug conjugate

Immunology

Monomethyl auristatin E

Click the tags to see associated articles and topics

ProfoundBio Announces First Patient Dosed in Phase 1/2 Clinical Trial of PRO1107 ... - PR Newswire. View article details on HISWAI: https://www.prnewswire.com/news-releases/profoundbio-announces-first-patient-dosed-in-phase-12-clinical-trial-of-pro1107-a-protein-tyrosine-kinase-7-ptk7-targeted-antibody-drug-conjugate-incorporating-a-novel-proprietary-hydrophilic-mmae-based-linker-drug-302052878.html

Excerpt

Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple ...

Article found on: www.prnewswire.com

View Original Article